REDHILL BIOPHAR/S (NASDAQ:RDHL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Saturday, Zacks.com reports.

According to Zacks, “RedHill Biopharma Ltd. is a specialty biopharmaceutical company, primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases. RedHill promotes the gastrointestinal drug Aemcolo(TM) in the U.S. and is planning to launch Talicia(TM) in the U.S. for the treatment of Helicobacter pylori (H. pylori) infection in adults. RedHill’s key clinical late-stage development programs include: RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; RHB-102 (Bekinda(TM)), for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; ABC294640 (Yeliva(TM)), a first-in-class SK2 selective inhibitor, targeting multiple oncology, inflammatory and gastrointestinal indications, with an ongoing Phase 2a study for cholangiocarcinoma; RHB-106, an encapsulated bowel preparation, and RHB-107. “

A number of other equities research analysts also recently weighed in on RDHL. Roth Capital cut their price target on shares of REDHILL BIOPHAR/S from to in a report on Thursday, February 27th. HC Wainwright reissued a “buy” rating and issued a $14.00 price target (down from $18.00) on shares of REDHILL BIOPHAR/S in a report on Thursday, March 5th. Finally, ValuEngine raised shares of REDHILL BIOPHAR/S from a “hold” rating to a “buy” rating in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $14.85.

Shares of NASDAQ RDHL opened at $4.35 on Friday. REDHILL BIOPHAR/S has a twelve month low of $3.50 and a twelve month high of $9.03. The company has a current ratio of 5.01, a quick ratio of 4.84 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $95.42 million, a price-to-earnings ratio of -3.27 and a beta of 1.67. The firm has a 50-day moving average of $4.90 and a two-hundred day moving average of $6.21.

A number of hedge funds and other institutional investors have recently modified their holdings of RDHL. Virtu Financial LLC purchased a new stake in REDHILL BIOPHAR/S during the fourth quarter valued at about $62,000. Schonfeld Strategic Advisors LLC purchased a new stake in REDHILL BIOPHAR/S during the fourth quarter valued at about $104,000. Ingalls & Snyder LLC purchased a new stake in REDHILL BIOPHAR/S during the fourth quarter valued at about $119,000. Boston Partners purchased a new stake in REDHILL BIOPHAR/S during the third quarter valued at about $190,000. Finally, Bank of New York Mellon Corp lifted its stake in REDHILL BIOPHAR/S by 100.0% during the fourth quarter. Bank of New York Mellon Corp now owns 34,000 shares of the biotechnology company’s stock valued at $206,000 after buying an additional 17,000 shares in the last quarter. 29.57% of the stock is owned by institutional investors.

About REDHILL BIOPHAR/S

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.

See Also: How to Invest in the Dividend Aristocrat Index

Get a free copy of the Zacks research report on REDHILL BIOPHAR/S (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.